Clinical Trial: Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07883759) titled 'Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.' on Sept. 14.

Brief Summary: This phase II trial examine whether neoadjuvant PD-1 blockade will achieve a pathological response with manageable toxicity in stage IIB/IIC melanoma.

Patients with histologically confirmed AJCC (8th edition) clinical stage IIB (T3b, T4a), or IIC (T4b) primary cutaneous melanoma from a partial biopsy, with residual macroscopic disease without metastases will be included. They will be treated with 2 infusions of Pembrolizumab followed by surgery and adjuvant treatment.

T...